Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Tanwi Tanwi

Neurology Petersburg, VA Medical Doctor

NPI 1285684902 CMS profile 58473

601 Old Wagner Rd, Suite 101, Petersburg, VA 23805

Open in the dashboard

General payments

$2,053

105 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Tanwi Tanwi of Petersburg, VA is reported in the CMS Open Payments database as having received $2,053 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $216 9
2023 General $427 19
2022 General $390 18
2021 General $178 9
2020 General $417 20
2019 General $425 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tanwi Tanwi
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Tanwi Tanwi were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Tanwi Tanwi Neurology median Middle half National median
2019 $425 $474 $118–$2,177 $163
2020 $417 $367 $82–$2,309 $114
2021 $178 $438 $104–$2,547 $132
2022 $390 $442 $103–$2,388 $149
2023 $427 $464 $119–$2,312 $160
2024 $216 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Mallinckrodt Hospital Products Inc. $322 16 payments
  2. EMD Serono, Inc. $286 16 payments
  3. GlaxoSmithKline, LLC. $215 11 payments
  4. Mallinckrodt Enterprises LLC $159 13 payments
  5. ANI Pharmaceuticals, Inc. $135 5 payments
  6. Paratek Pharmaceuticals, Inc. $110 6 payments
  7. Biogen, Inc. $92 5 payments
  8. Supernus Pharmaceuticals, Inc. $90 2 payments
  9. Actelion Pharmaceuticals US, Inc. $88 4 payments
  10. Inspire Medical Systems, Inc. $71 3 payments
  11. Other $486 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,053 105 payments
Products named General payments · program years 2019–2024
  1. ACTHAR Immunology $322 16 payments
  2. TRELEGY ELLIPTA $215 11 payments
  3. ACTHAR Autoimmune And Rare Disease $159 13 payments
  4. PURIFIED CORTROPHIN GEL $110 4 payments
  5. NUZYRA $110 6 payments
  6. Mavenclad Neurology $103 7 payments
  7. UPTRAVI $88 4 payments
  8. REBIF $85 5 payments
  9. MAVENCLAD Neurology $80 3 payments
  10. INSPIRE $71 3 payments
  11. Other $975 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,396

Median for Neurology: 833

Drug cost

$617,786

Median for Neurology: $202,670

Branded share of claims

20.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rebif Rebidose Interferon Beta-1a/Albumin Brand 21 $218,716
Avonex Pen (4 Pack) Interferon Beta-1a Brand 21 $164,832
Avonex (4 Pack) Interferon Beta-1a Brand 11 $85,651
Dimethyl Fumarate Generic 43 $63,832
Glatiramer Acetate Generic 11 $56,158
Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone Brand 32 $6,217
Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine Brand 58 $3,451
Oxcarbazepine Generic 45 $2,283
Memantine Hcl Generic 87 $2,200
Gabapentin Generic 160 $1,990

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$10,923

Medicare's payments for the services billed

Medicare patients

86

Average age 74

Services billed

114

57 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 47%
Chronic kidney disease 44%
Depression 33%
Ischemic heart disease 29%
Heart failure 27%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ACTHAR
  • Mallinckrodt Hospital Products Inc. $28
$28 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $25
$25 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $24
$24 — —
AREXVY
  • GlaxoSmithKline, LLC. $24
$24 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record